left IPL stimulation for Autism Spectrum Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorder+3 More
Trans Cranial Magnetic Stimulation - Device
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether transcranial direct current stimulation (tDCS) can help people with ASD by improving social cognition and communication skills.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism Spectrum Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: at baseline and 5 weeks of rTMS

Week 5
The effect of rTMS on verbal fluency
The effects of rTMS on executive function
Week 5
The effects of rTMS on reciprocal rigid patterns of behavior
The effects of rTMS on reciprocal social cognition

Trial Safety

Trial Design

2 Treatment Groups

left IPL stimulation
1 of 2
right IPL stimulation
1 of 2
Active Control

30 Total Participants · 2 Treatment Groups

Primary Treatment: left IPL stimulation · No Placebo Group · N/A

left IPL stimulation
Device
ActiveComparator Group · 1 Intervention: Trans Cranial Magnetic Stimulation · Intervention Types: Device
right IPL stimulation
Device
ActiveComparator Group · 1 Intervention: Trans Cranial Magnetic Stimulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at baseline and 5 weeks of rtms

Who is running the clinical trial?

Christiana Care Health ServicesLead Sponsor
110 Previous Clinical Trials
104,023 Total Patients Enrolled
Dupont Applied BiosciencesIndustry Sponsor
11 Previous Clinical Trials
2,854 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: October 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.